KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $7.4 million.

  • AbCellera Biologics' Cash from Financing Activities rose 13440.38% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year increase of 1385.57%. This contributed to the annual value of $12.8 million for FY2024, which is 2330.05% up from last year.
  • As of Q3 2025, AbCellera Biologics' Cash from Financing Activities stood at $7.4 million, which was up 13440.38% from -$3.4 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Cash from Financing Activities ranged from a high of $7.4 million in Q3 2025 and a low of -$5.1 million during Q2 2021
  • In the last 5 years, AbCellera Biologics' Cash from Financing Activities had a median value of $1.2 million in 2022 and averaged $1.5 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 156676.3% in 2021, then surged by 3499473.68% in 2023.
  • Quarter analysis of 5 years shows AbCellera Biologics' Cash from Financing Activities stood at $1.8 million in 2021, then crashed by 80.97% to $349000.0 in 2022, then skyrocketed by 978.8% to $3.8 million in 2023, then grew by 10.01% to $4.1 million in 2024, then surged by 77.98% to $7.4 million in 2025.
  • Its Cash from Financing Activities stands at $7.4 million for Q3 2025, versus -$3.4 million for Q2 2025 and $6.0 million for Q1 2025.